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Introduction
Alzheimer’s disease (AD) affects  4.5 million Americans, and 
this number will continue to grow. By 2050, the number of indi-
viduals with AD could range from 11.3 to 16 million (Hebert 
et al., 2003). The pathogenesis underlying AD remains unclear, 
and it is controversial whether AD results from a primary abnor-
mality in amyloid precursor protein (APP) or deregulation of 
the infl  ammatory system (Weiner and Selkoe, 2002), although 
these two possibilities are not mutually exclusive. Several lines 
of evidence implicate abnormal processing of APP, which is 
cleaved by two enzymes, β-secretase 1 (BACE1) and γ-secretase, 
to generate excessive amyloid β protein (Aβ), as a potential 
cause of AD (Selkoe, 2003; Tanzi and Bertram, 2005). In the past 
decade, transgenic mice have been generated that overexpress 
mutant APP and display Aβ-related lesions (Hsiao et al., 1995). 
Many of these mouse models exhibit amyloid plaque-predominant 
aspects of AD (Terry et al., 1987; Tiraboschi et al., 2004), including 
Aβ plaque formation, cerebral amyloid angiopathy (CAA), and 
infl  ammation, but not τ pathology.
The TNF death receptor belongs to the TNFR superfamily, 
which includes >20 cell surface receptors. When the TNF type 1 
death receptor (TNFR1) binds to its ligand, TNFα, the ligand–
receptor complex triggers apoptotic pathways by recruiting a 
TNFR-associated death domain protein and/or a Fas-associated 
death domain protein/mediator of receptor-induced toxicity, two 
intracellular adaptor proteins (Boldin et al., 1995). The receptor-
induced multimerization of a Fas-associated death domain 
protein leads to caspase activation, which causes degradation 
of specifi  c target proteins, ultimately damaging cell integrity 
(Ashkenazi and Dixit, 1998).
To fi nd out whether TNFR1 could have effect on Aβ pro-
duction as well as APP processing, we specifi  cally chose trans-
genic APP23 mice in our experiments, which express a mutant 
APP that results in extensive Aβ plaque formation. Here we 
show that fewer Aβ plaques and Aβ-related lesions develop in 
Alzheimer’s transgenic mice with genetic deletion of TNFR1. 
Detailed analyses showed decreased Aβ generation, less neuro-
nal loss, and alleviated Aβ-related memory defi  cits. Our data 
indicates that TNFR1 might be a potential and novel therapeutic 
target for AD.
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T
he tumor necrosis factor type 1 death receptor 
(TNFR1) contributes to apoptosis. TNFR1, a sub-
group of the TNFR superfamily, contains a cyto-
plasmic death domain. We recently demonstrated that the 
TNFR1 cascade is required for amyloid β protein (Aβ)–
  induced neuronal death. However, the function of TNFR1 
in Aβ plaque pathology and amyloid precursor protein 
(APP) processing in Alzheimer’s disease (AD) remains 
unclear. We report that the deletion of the TNFR1 gene 
in APP23 transgenic mice (APP23/TNFR1
−/−) inhibits 
Aβ generation and diminishes Aβ plaque formation in 
the brain. Genetic deletion of TNFR1 leads to reduced 
β-secretase 1 (BACE1) levels and activity. TNFR1 regulates 
BACE1 promoter activity via the nuclear factor-κB path-
way, and the deletion of TNFR1 in APP23 transgenic mice 
prevents learning and memory deﬁ   cits. These ﬁ  ndings 
suggest that TNFR1 not only contributes to neurodegener-
ation but also that it is involved in APP processing and Aβ 
plaque formation. Thus, TNFR1 is a novel therapeutic 
  target for AD.
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Results
TNFR1 deletion reduces 
A𝗃-related pathology
APP23 transgenic mice (Sommer and Staufenbiel, 1998), a mouse 
model for AD with a plaque-predominant type (Terry et al., 
1987; Tiraboschi et al., 2004), overproduce Aβ, Aβ40, and 
Aβ42, and develop signifi  cant amyloid deposits by the age of 
14 mo. To determine whether genetic inactivation of TNFR1 
delays or diminishes Aβ plaque formation, we crossed APP23 
mice with mice lacking the TNFR1 gene (TNFR1
−/−; Peschon 
et al., 1998) to generate APP23/TNFR1
−/− mice. To evaluate Aβ 
pathology in the brains, we fi  rst used Congo red staining to see 
if reduced protein aggregation could be observed in the brains 
of APP23/TNFR1
−/− mice. Congo red has been shown to be 
affi  nitive for binding to fi  bril proteins enriched in β-sheet con-
formation, and it is commonly used as a histological dye for 
amyloid detection (Frid et al., 2006). Results showed much less 
Congo red staining in APP23/TNFR1
−/− mice (Fig. 1 A), in-
dicating that protein aggregation was alleviated in APP23/
TNFR1
−/− mice.
To further confi  rm that the aggregated protein we found 
was aggregated Aβ peptide, we next examined the brain section 
with anti-Aβ antibody 6E10 (Vassar et al., 1999; Van Dooren 
et al. 2006). At 12 mo of age, APP23 mice displayed numerous 
Aβ plaques throughout the entorhinal cortex and hippocampus, 
consistent with a previous paper (Sommer and Staufenbiel, 1998). 
In APP23/TNFR1
−/− mice, however, we found only minor Aβ 
plaques in the entorhinal cortex (Fig. 1, B and C) and the hippo-
campus (Fig. 1, D and E). At 24 mo of age, APP23/TNFR1
−/− 
mice also displayed reduced plaques (Fig. 1, B and D). The 
number of plaques was reduced by 73 and 80% in the entorhinal 
cortex (Fig. 1 C) and hippocampus (Fig. 1 E) in APP23/TNFR1
−/− 
mice at 12 mo of age, indicating that Aβ pathology in APP23/
TNFR1
−/− indeed alleviated plaque formation compared with 
age-matched APP23 mice.
The size of Aβ plaques also indicates the severity of Aβ 
pathology (Zhou et al., 2005). We used morphometric analyses 
on the brain sections immunostained with Aβ antibody 6E10. 
Results showed that both large (>20 μm diameter)- and me-
dium (10–20 μm diameter)-sized Aβ plaques in the entorhinal 
cortex (Fig. 1 F) and hippocampus (Fig. 1 G) were signifi  cantly 
reduced in APP23/TNFR1
−/− mice at 12 and 24 mo of age, indi-
cating that in APP23/TNFR1
−/− mice, Aβ pathology was allevi-
ated not only by reducing the overall Aβ plaque number, but 
also by decreasing plaque size.
TNFR1 deletion reduces CAA
CAA has been reported to have both positive and negative cor-
relations with AD pathology (Cohen et al., 1997; Thal et al., 2003; 
Tian et al., 2003). It has been shown that CAA in APP23 trans-
genic mice is strikingly similar to that of human CAA (Calhoun 
et al., 1999). To fi  nd out whether genetic deletion of TNFR1 
can relieve CAA in APP23 mice, the deposition of Aβ in the 
vascular wall was examined by double immunostaining with 
antibodies against β-smooth muscle actin (a vascular smooth 
muscle marker; Skalli et al., 1986) or von Willebrand factor 
(vWF; an endothelial cell marker; Shyu et al., 2006) and 
anti-Aβ40 antibody. We found that at 24 mo of age, APP23 
mice display CAA predominant in cortical, hippocampal, and 
thalamic vessels; Aβ40 formed a continuous ring-like shape 
within the vessel wall (Fig. 2, A and B), consistent with Calhoun 
et al. (1999). However, there were very few Aβ40 deposits within 
the vessels of APP23/TNFR1
−/− (Fig. 2, C and D). Deposition 
of Aβ on the vascular wall could not only increase the vulnera-
bility of cerebral vessels but also increase the possibility of intra-
cerebral hemorrhage (Vinters, 1987; Itoh et al., 1993; Winkler 
et al., 2001; Atwood et al., 2003). Our results showed little CAA 
progression in the brains of APP23/TNFR1
−/− mice, suggesting 
that deletion of TNFR1 could reduce the risk of CAA.
TNFR1 deletion reduces 
microglia activation
Microglia activation is also a hallmark of Aβ pathology pro-
gression (Yan et al., 2003 ;Wilcock et al., 2004; Simard et al., 
2006). CD11b and CD45 are two well-characterized markers 
for microglia activation in the brains (Yan et al., 2003; Wilcock 
et al., 2004; Simard et al., 2006).To examine whether deletion 
of TNFR1 could alleviate the massive microglia activation of 
APP23 mice, we studied the microglia activation in APP23 
and APP23/TNFR1
−/− mice. Consistent with a previous paper 
(Wilcock et al., 2003), APP23 mice showed strong immuno-
reactivity with antibodies against CD11b (Mac-1) and CD45 in 
the entorhinal cortex (Fig. 3 A) and hippocampus (Fig. 3 B), in-
dicating that a massive amount of microglia had been activated 
along with the appearance of Aβ pathology. In contrast, APP23/
TNFR1
−/− mice showed signifi  cantly less CD11b and CD45 
immunoreactivity in the entorhinal cortex (Fig. 3 A) and hippo-
campus (Fig. 3 B), indicating that genetic deletion of TNFR1 
alleviated massive microglia activation in APP23 mice.
TNFR1 deletion reduces A𝗃 production
Because we found reduced Aβ pathology in APP23/TNFR1
−/− 
mice, our next question was whether genetic inactivation of 
TNFR1 reduces Aβ pathology by affecting Aβ generation. The 
Aβ level was analyzed by immunoprecipitation followed by 
Western blotting (n = 3 for each group). Fig. 4 A shows a repre-
sentative urea Western blot (Wiltfang et al., 1997) comparing the 
4-kD Aβ species (n = 3 for each group). Both Aβ40 and Aβ42 
can be detected, and Aβ42 migrated ahead of Aβ40, consistent 
with a previous paper (Wiltfang et al., 1997). Compared with 
APP23 mice, APP23/TNFR1
−/− mice showed a signifi  cant re-
duction in both Aβ40 and Aβ42 levels (Fig. 4 A). We further 
measured total Aβ, Aβ40, and Aβ42 levels by sandwich ELISAs 
(n = 10 for each group). The results bolstered our Western blot 
fi  ndings and confi  rmed that APP23/TNFR1
−/− mice have much 
less total Aβ, Aβ40, and Aβ42 (Fig. 4, B–D). Quantitatively, 
total Aβ decreased by 69% (37.39 ± 12.71 ng/mg) and 30% 
(463.87  ± 189.83 ng/mg) in 12- and 24-mo-old APP23/
TNFR1
−/− mice, respectively, compared with total Aβ in APP23 
mice (12 mo old:  120.80 ± 39.74 ng/mg; 24 mo old: 693.40 ± 
270.27 ng/mg; Fig. 4 B). Both Aβ40 and Aβ42 were reduced 
in APP23/TNFR1
−/− mice. However, the most signifi  cant dif-
ference is at 12 mo of age, when Aβ40 decreased by 80% in TNFR1 AFFECTS APP PROCESSING AND MEMORY • HE ET AL. 831
Figure 1.  A𝗃 deposition is signiﬁ  cantly reduced in APP23/TNFR1
−/− mice. (A) Congo red showed fewer congophilic deposits in the brains of APP23/
TNFR1
−/− mice at both 12 and 24 mo of age. (B) 6E10-immunostained sections of the entorhinal cortex. (C) Stereological analyses of 6E10-immunostained 
sections revealed fewer immunoreactive plaques in the entorhinal cortex of APP23/TNFR1
−/− mice. (D) 6E10-immunostained sections of the hippocampus. 
(E) Stereological analyses of 6E10-immunostained sections revealed fewer immunoreactive plaques in the hippocampus of APP23/TNFR1
−/− mice (*, P < 0.05). 
(F) Fewer large plaques (>20 μm) were found in the entorhinal cortex of APP23/TNFR1
−/− mice. (G) Fewer large plaques (>20 μm) were found in the 
hippocampus of APP23/TNFR1
−/− mice. Error bars represent SD. Bars, 50 μm.JCB • VOLUME 178 • NUMBER 5 • 2007  832
APP23/TNFR1
−/− mice (20.45 ± 4.7 ng/mg) compared with 
APP23 mice (103.87 ± 21.81 ng/mg; Fig. 4 C), and Aβ42-
decreased by 70% in APP23/TNFR1
−/− mice (4.12 ± 1.2 ng/mg) 
compared to APP23 mice (15.78 ± 4.7 ng/mg; Fig. 4 D). These re-
sults indicated that reduction in Aβ40 and Aβ42 levels could ac-
count for the alleviated Aβ pathology in APP23/TNFR1
−/− mice.
One of the mechanisms that could infl  uence Aβ production 
is through altering APP holoprotein levels. We next analyzed by 
Western blot to see if deletion of TNFR1 affects APP protein 
levels (n = 3 for each group). In contrast to the reduction in Aβ 
levels, Western blotting did not reveal any differences in full-length 
APP levels between APP23/TNFR1
−/− and APP23 mice (Fig. 4 E), 
indicating that the decrease in Aβ levels was not caused by altering 
APP protein expression in APP23/TNFR1
−/− mice.
TNFR1 deletion alters BACE1 
activity and level
To examine whether the reduced amyloidosis in APP23/
TNFR1
−/− mice was caused by a reduction in abnormal APP 
metabolism, we examined the activity and expression levels of 
one key enzyme in APP processing, BACE1.
We fi rst used an MCA-labeled BACE1 substrate (Yang 
et al., 2003; Li et al., 2004a) to examine BACE1 activity and 
found that BACE1 activity was significantly decreased in 
APP23/TNFR1
−/− mice (Fig. 5 A). To fi  nd out whether the de-
creased BACE1 activity was due to a decrease in BACE1 levels, 
we measured BACE1 levels by sandwich ELISA (Yang et al., 
2003) and Western blot (n = 3 for each group). We found that 
BACE1 levels in APP23/TNFR1
−/− mice were indeed reduced 
in both Western blot and ELISA results (Fig. 5, B and C), indi-
cating that reduced BACE1 activity in APP23/TNFR1
−/− mice was 
caused by a reduction in the protein level. To further investigate 
whether reduced BACE1 protein level is caused by reduced 
BACE1 mRNA transcription, we performed RT-PCR to mea-
sure BACE1 mRNA levels and found that BACE1 mRNA was 
also decreased in APP23/TNFR1
−/− mice (Fig. 5 D), indicating 
that the genetic deletion of TNFR1 reduced BACE1 mRNA lev-
els and caused BACE1 activity to be down-regulated in APP23/
TNFR1
−/− mice.
TNF𝗂 regulates BACE1 transcription 
through the TNFR1–nuclear factor 𝗋B 
(NF-𝗋B) pathway
Our RT-PCR results showed that BACE1 mRNA levels de-
creased in APP23/TNFR1
−/− mice; the next question was what 
signal transduction pathway leads to the decreased BACE1 
mRNA level.
To clarify how deletion of TNFR1 affects BACE1, we 
transfected 293 cells with a pB1P-A vector containing a BACE1 
promoter (−1941 to +292) that was upstream of a luciferase 
reporter gene (Christensen et al., 2004; Sambamurti et al., 
2004), and then treated these cells with different concentrations 
of TNFα. We found that BACE1 promoter activity increased in 
a concentration-dependent manner (Fig. 6 A). Blocking the 
interaction of TNFα with the extracellular domain fragment of 
TNFR1 inhibited such elevation in BACE1 promoter activity 
(Fig. 6 A), indicating that TNFα activates BACE1 promoter 
through TNFR1.
Figure 2.  Cerebral vascular amyloid deposits were reduced in APP23/TNFR1
−/− mice. (A) 6E10 immunostaining showed that microvascular Aβ deposits 
were reduced in the frontal cortex of APP23/TNFR1
−/− mice. (B) Vascular Aβ deposits were reduced in the thalamus of APP23/TNFR1
−/− mice. (C) Double 
labeling of α-smooth muscle actin (α-SM actin; red) and Aβ40 (green) showed fewer Aβ40 deposits on microvascular walls of 24-mo-old APP23/TNFR1
−/− 
mice than in age-matched APP23 mice (arrow points to absence of Aβ deposits on one smaller vascular wall). (D) Double labeling of 6E10 and vWF anti-
body showed fewer Aβ deposits on the vascular walls of 24-mo-old APP23/TNFR1
−/− mice (arrow points to an Aβ plaque that appears to be outside of 
the vascular wall in the cortex of APP23/TNFR1
−/− mice). Bars: (A and B) 50 μm; (C and D) 5 μm. TNFR1 AFFECTS APP PROCESSING AND MEMORY • HE ET AL. 833
NF-κB is one of the major mediators of TNFα-activated 
TNFR1 signaling (Hsu et al., 1995; Yang et al., 2002). A recent 
fi  nding that multiple NF-κB binding sites are located in the 
vicinity of BACE1 promoter (Sambamurti et al., 2004) suggests 
that NF-κB may play an important role in regulating BACE1 
transcription. To determine whether TNFR1 activates the BACE1 
promoter through this pathway, we used the potent NF-κB acti-
vation inhibitor 6-amino-4(4-phenoxyphenylethylamino) quin-
azoline (Tobe et al., 2003) to block NF-κB signaling in TNFα-
treated 293 cells transfected with a BACE1 promoter luciferase 
reporter vector. Treating a pB1P-A transfected cell with an 
NF-κB inhibitor signifi  cantly reduced TNFα-induced BACE1 
promoter activity (Fig. 6 B). A high concentration of NF-κB in-
hibitor inhibited not only TNFα-induced BACE1 promoter ac-
tivity but also basal promoter activity (Fig. 6 B), indicating that 
NF-κB may play a central role in regulating BACE1 transcription. 
Thus, the TNFα-mediated activation of NF-κB through TNFR1 
represents a key part of this regulatory pathway.
These fi  ndings indicate that one mechanism underlying the 
regulation of BACE1 transcription may be through TNFR1-
mediated activation of NF-κB. We found signifi  cantly lower Aβ 
as well as BACE1 levels in APP23/TNFR1
−/− in older specimens 
(12 and 24 mo). One possible explanation is that when Aβ deposits 
are lower (at both time points), there is less Aβ to extract, there-
fore lower Aβ levels might not be caused by the reduced BACE1 
level. To examine whether the reduced Aβ level is caused by the 
reduced BACE1 level, we measured Aβ and BACE1 levels in 
APP23/TNFR1
−/− mice at 6 mo of age, before Aβ pathology can 
be observed. If TNFR1 affects the BACE1 level, it should also 
reduce the BACE1 level at this age. We fi  rst found that total Aβ 
in APP23/TNFR1
−/− mice was much lower than in APP23 mice 
(Fig. 7 A). Both Aβ40 and Aβ42 levels in APP23/TNFR1
−/− 
mice were also reduced. A Western blot showed a reduction of 
the BACE1 protein level in APP23/TNFR1
−/− mice (Fig. 7 B). 
BACE1 RT-PCR showed a similar result to that of 12-mo-old 
mice; the BACE1 mRNA level was signifi  cantly lower in APP23/
TNFR1
−/− mice than in APP23 mice (Fig. 7 C). Together, these 
fi  ndings indicate that TNFR1 indeed regulates the BACE1 mRNA 
level, and that Aβ reduction in APP23 mice after genetic deletion 
of TNFR1 is caused by decreased BACE1 levels.
TNFR1 deletion has little effect on A𝗃 
clearance enzymes insulin degradation 
enzyme (IDE) and neprilysin (NEP)
Aβ reduction could also be caused by an increase in Aβ 
degradation/clearance activity, which is not relevant to Aβ 
production. To determine whether deletion of TNFR1 reduces 
Aβ deposition by affecting enzymes involved in Aβ degrada-
tion, we assessed the protein levels of IDE and NEP, two enzymes 
that play an important role in Aβ degradation and clearance 
(Farris et al., 2003). Western blot analyses did not show signifi  -
cant differences in either IDE or NEP levels between APP23/
TNFR1
−/− and APP23 mice (Fig. 8 A), suggesting that deletion 
of TNFR1 did not interfere with IDE and NEP expression. To fi  nd 
out whether deletion of TNFR1 could have an effect on IDE or NEP 
activity, we further compared both IDE and NEP activity between 
APP23 and APP23/TNFR1
−/− mice. Again, no signifi  cant dif-
ference was observed (Fig. 8, B and C). Therefore, IDE and NEP 
were not responsible for the reduction of the Aβ level associated 
with the TNFR1 deletion.
TNFR1 deletion ameliorates neuron loss
We recently reported that TNFR1 plays a critical role in Aβ-
induced neuronal death (Li et al., 2004b). To determine whether 
the deletion of TNFR1 protects neurons, we compared neuronal 
loss in wild-type, APP23/TNFR1
−/−, and APP23 mice. Com-
pared with wild-type mice, APP23 mice show a 30% reduction 
in NeuN-positive cells in the entorhinal cortex, whereas APP23/
TNFR1
−/− mice show no signifi  cant reduction at 24 mo of age 
(Fig. 9, A and C). Results were similar in the hippocampus, 
where APP23 mice had 15% fewer NeuN-positive cells in the 
CA1 area of the hippocampus (Fig. 9 B, D; Calhoun et al., 
1998), whereas little neuronal loss was seen in APP23/TNFR1
−/−
mice at 24 mo of age (Fig. 9, B and D). We found similar results 
using Nissl-stained brain sections (not depicted).
TNFR1 deletion lessens memory deﬁ  cits 
typical of APP23 mice
To examine the behavioral signifi  cance of TNFR1 deletion, we 
tested wild-type, APP23, APP23/TNFR1
−/−, and TNFR1
−/− 
Figure 3.  Microglia activation is reduced in the brains of APP23/TNFR1
−/−
mice. (A) The sections were immunostained with CD11b, an activated 
microglia marker, in the entorhinal cortex. (B) The sections were immuno-
stained with CD11b in the hippocampus. Bars, 50 μm. JCB • VOLUME 178 • NUMBER 5 • 2007  834
mice with a hole-board memory test, which is a behavioral 
task widely used to assess exploratory learning and memory 
(Garcia, 1987; Thifault et al., 2002). The majority of APP23 mice 
showed signifi  cant defi  cits in the spatial component of the test. 
However, exploratory learning and memory retention (percent-
age of correct pokes) of APP23/TNFR1
−/− mice was not sig-
nifi  cantly different from that of wild-type or TNFR1
−/− mice 
(Fig. 10 A). This suggests that deletion of TNFR1, which could 
lead to a reduction of Aβ levels as well as neuronal protection, 
might have an effect on improving spatial learning perfor-
mance in APP23/TNFR1
−/− mice (Fig. 10 A). The correlation be-
tween Aβ reduction/neuronal protection and improved learning 
and memory behaviors remained strong when the percentages 
of correct pokes were averaged over all hidden hole-board 
trials (Fig. 10 A). Specifi  cally, we found that 6-mo-old APP23 
mice made more errors than did age-matched wild-type mice 
across 3 d of testing (group effect, F1,15 = 22.198, P < 0.001). 
However, percentage correct scores of APP23/TNFR1
−/− mice 
were markedly higher than those of APP23 mice. APP23/
TNFR1
−/− mice made signifi  cantly fewer errors than did APP23 
mice on days 2 and 3 of testing (group effect, F1,20 = 8.957, 
P < 0.05).
The object recognition task is based on the spontaneous 
exploration of novel and familiar objects. Mice will spend more 
time exploring a novel object than a familiar one (Pittenger 
et al., 2002; Bourtchouladze et al., 2003; Wang et al., 2004). We 
further examined whether deletion of TNFR1 could rescue ob-
ject recognition defi  cits in APP23 mice. Object recognition per-
formance was much better in APP23/TNFR1
−/− mice than in 
APP23 mice, as the recognition indexes differed signifi  cantly 
between these groups (group effect, F3,31 = 24.947, P < 0.001; 
Fig. 10 B). APP23/TNFR1
−/− mice performed comparably to 
Figure 4.  Deletion of TNFR1 reduces A𝗃 
production. (A) Western blot showed reduced 
Aβ40 and Aβ42 in APP23/TNFR1
−/− mice at 
both 12 and 24 mo of age. (B) Total Aβ ELISA 
was calculated as nanogram per milligram of 
protein. (C) Aβ40 ELISA was calculated as 
nanogram per milligram of protein. (D) Aβ42 
ELISA was calculated as picogram per milli-
gram of protein (*, P < 0.05). (E) Western 
blot of brain lysates (50 μg protein) showed 
the APP expression. No change in APP expres-
sion was observed. Error bars represent SD. TNFR1 AFFECTS APP PROCESSING AND MEMORY • HE ET AL. 835
age-matched wild-type mice. In addition, within-group t-test 
analyses confi  rmed that APP23/TNFR1
−/− mice (t = 8.872, 
P < 0.001) and wild-type mice (t = 10.024, P < 0.001) per-
formed above chance values  (50%), whereas APP23 mice did 
not (t = 0.092). This result suggests that deletion of TNFR1 in 
APP23 mice not only improves learning and memory in the 
hole-board behavioral test but also enhances performance in 
objective recognition.
Discussion
TNFR is a family of TNF receptors, TNFR1 and TNFR2 (Tartaglia 
et al., 1993), both of which bind soluble Aβ40 (Li et al., 2004b). 
Overexpression of TNFR1 promotes Aβ-induced neuronal death 
(Li et al., 2004b). It has been reported that a higher infl  amma-
tory response was observed in MCI and AD patients (Cagnin 
et al., 2001; Tarkowski et al., 2003 ;Galimberti et al., 2006), 
Figure 5.  Deletion of TNFR1 reduced BACE1 
protein levels and activity. (A) BACE1 activ-
ity assay showed reduced BACE1 activity in 
APP23/TNFR1
−/− mice at 12 and 24 mo, 
compared with APP23 mice. The activity was 
normalized to the input protein amount and 
indicated as an arbitrary unit (*, P < 0.05). 
(B) Western blot of BACE1 in wild-type, 
APP23/TNFR1
−/−, and APP23 mice. BACE1 
expression levels were reduced in APP23/
TNFR1
−/− mice. (C) BACE1 ELISA showed 
that the BACE1 level was reduced in APP23/
TNFR1
−/− mice compared with APP23 and 
wild-type mice. BACE1 concentrations were 
calculated using a BACE1 standard curve. 
Concentrations are expressed as microgram 
per milligram of total protein (*, P < 0.05). 
(D) RT-PCR of BACE1 from the brains of APP23 
and APP23/TNFR1
−/− mice, mouse ribosomal 
subunit protein s18 was used as a loading 
control. BACE1 mRNA was decreased in 
APP23/TNFR1
−/− mice. Error bars represent SD. JCB • VOLUME 178 • NUMBER 5 • 2007  836
and infl  ammatory cytokines and free radicals can up-regulate 
BACE1 expression (Tamagno et al., 2002; Hong et al., 2003; Pak 
et al., 2005; Tamagno et al., 2005; Sastre et al., 2006). TNFα is 
one of the up-regulated infl  ammation factors in APP transgenic 
mice (Patel et al., 2005). Here we found that TNFR1 could di-
rectly regulate BACE1 transcription through NF-κB, which is 
one of the major mediators of TNFα-activated TNFR1 signaling 
(Hsu et al., 1995; Yang et al., 2002). Recent fi  ndings showed 
multiple NF-κB binding sites located in the vicinity of BACE1 
promoter (Sambamurti et al., 2004), suggesting that NF-κB may 
play an important role in regulating BACE1 transcription. This 
is confi  rmed by our results that the NF-κB inhibitor inhibits 
BACE1 promoter activity.
At 24 mo of age, we found signifi  cant neuronal loss in 
APP23 mice. However, Irizarry et al. (1997) did not observe 
neuronal loss in 16-mo-old APP transgenic mice (Tg2576) ex-
pressing the APPK670N/M671L mutation, the same mutation 
harbored by APP23 mice. This might be because the APP trans-
gene is controlled by different promoters in APP23 and Tg2576 
mice (Irizarry et al., 1997; Sturchler-Pierrat et al., 1997). TNFR1 
defi  ciency ameliorates neuron loss in APP23 mice, consistent 
with our previous fi  ndings that TNFR1 overexpression increases 
the vulnerability of cultured hippocampal neurons to Aβ-induced 
death and promotes neuronal degeneration (Li et al., 2004b). 
We also noticed that TNFα plays different roles in neuronal death 
and survival via its distinct receptors, TNFR1 and TNFR2. Neuron 
loss in APP23 mice caused by “endogenous” Aβ may be con-
ducted through different signal transduction pathways. Moreover, 
Barger et al. (1995) showed that TNFα can protect neurons 
derived from fetal brains against Aβ toxicity. Our unpublished 
data show that TNFR1 is expressed at a low level, whereas TNFR2 
is expressed at a high level in fetal neurons. This may explain why 
TNFα is trophic in fetal neurons. Interestingly, Bruce et al. 
(1996) discovered that neurons from mice with a defi  ciency 
of both TNFR1 and TNFR2 are more sensitive to excitotoxic 
  injury. This result is interesting because the fi  nding suggests 
that there is a balance between TNFR1 and TNFR2 expression 
levels in neurons, and TNFR2 seems to be more critical and more 
sensitive to neurons.
Our behavioral analyses revealed that inactivation of 
TNFR1 rescued hippocampal-dependent learning and memory 
defi  cits displayed by young APP23 mice (Van Dam et al., 2003). 
A previous study reported that disruption of the BACE1 gene or 
PS1 in APP transgenic mice rescues memory defi  cits measured 
by social recognition and spatial alternation tasks (Saura et al., 
2005). This is consistent with our fi  ndings in APP23/TNFR1
−/− 
mice, presumably because TNFR1 depletion decreases Aβ pro-
duction and deposition, thereby reducing Aβ-related memory 
defi  cits. The relatively normal performance of hippocampal-
  dependent memory tasks by APP23/TNFR1
−/− mice is age 
related. At 6 mo of age, APP23/TNFR1
−/− mice already performed 
hippocampal-dependent memory tasks better than APP23 mice. 
Furthermore, TNFR1 knockout mice exhibited normal synaptic 
transmission and plasticity in the Schaffer collateral pathway 
(unpublished data). Our results allow us to determine whether 
treating APP23 mice with anti-TNFR1 antibody or inhibitors of 
the TNFR1 signal transduction pathway could reduce BACE1 
and cerebral Aβ.
Materials and methods
Generation of APP transgenic AD mice with deletion of TNFR1
TNFR1 knockout mice (TNFR1
−/−) were constructed on a C57BL/6 back-
ground as previously described (Peschon et al., 1998). APP23 transgenic 
mice were provided by Novartis Institute for Biomedical Research; these 
Figure 6.  TNFR1 regulates BACE1 promoter activity through NF-𝗋B. (A) TNFα induces BACE1 promoter activity. (B) NF-κB inhibits TNFα-induced BACE1 
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mice express mutant human βAPP (Swedish double mutation, KM670/
671NL) under the control of a brain- and neuron-speciﬁ  c murine Thy-1 
promoter element. APP23 transgenic mice develop senile plaques in the 
cerebral cortex and hippocampus and show neuronal loss at 12–18 mo of 
age; this pathology is most evident in area CA1 of the hippocampus 
(Sommer and Staufenbiel, 1998). APP23 mice were also constructed on a 
C57BL/6 background.
APP23 and TNFR1
−/− mice were crossed and their progeny were 
genotyped. An APP23/TNFR1
+/− mouse was backcrossed with TNFR1
−/− 
mice to produce APP23/TNFR1
−/− mice. To maintain the heterozygous 
APP transgene in our mice, we crossed APP23 mice with wild-type C57BL/6 
mice. For APP23/TNFR1
−/− mice, we crossed APP23/TNFR1
−/− with 
TNFR1
−/− mice for three to ﬁ  ve generations. Therefore, both APP23 and 
APP23/TNFR1
−/− mice were APP23
+/−. We used APP23/TNFR1
−/− mice 
of the F3–F5 generation in our experiments.
Mice homozygous for the TNFR1 targeted mutation (formerly TNFR1, 
p55 deﬁ  cient) show defects in resistance to intracellular pathogens and are 
resistant to the lethal effects of lipopolysaccharide administration in 
conjunction with D-galactosamine. Pulmonary inﬂ  ammatory responses are 
diminished in p55-deﬁ  cient mice. There are also defects in splenic architec-
ture, formation of germinal centers, and liver regeneration. TNFR1- deﬁ  cient 
mice display increased susceptibility to atherosclerosis when maintained 
on a high-fat diet (Peschon et al., 1998). No observations regarding any 
syndromes of the central nervous system have been made.
ELISA
APP23, APP23/TNFR1
−/−, and wild-type mice (n = 10 per group) were 
killed at 12 and 24 mo of age, and one hemisphere of the brain was ho-
mogenized in homogenization buffer (250 mM sucrose, 20 mM Tris-HCl, 
pH 7.4, 1 mM EDTA, and 1 mM EGTA). An aliquot of the homogenate 
was dissolved in formic acid and neutralized with a neutralization buffer 
(1 mM Tris and 0.5 M Na2HPO4). Protein concentration was measured by 
protein assay (Bio-Rad Laboratories). For total Aβ ELISA, the capture anti-
body was monoclonal anti-Aβ antibody 4G8 (Chemicon), and the detec-
tion antibody was biotinylated monoclonal antibody anti-Aβ 6E10 (AbD 
Serotec). Aβ40 and Aβ42 were measured with an Aβ40 and Aβ42 ELISA 
kit (Biosource International). The ELISA system has been extensively tested 
and no cross-reactivity between Aβ40 and Aβ42 was observed. Data are 
presented as means ± SD of four experiments.
BACE1 protein levels were measured by ELISA as described previ-
ously (Yang et al., 2003). The capture antibody was anti-BACE1 poly-
clonal antibody P1 (Yang et al., 2003) and the detection antibody was 
biotinylated anti-BACE1 polyclonal antibody P2 (Yang et al., 2003). 
TMB substrate was used to visualize the reaction product, which was 
Figure 7.  A𝗃 and BACE1 levels are reduced in APP23/TNFR1
−/− mice as 
early as 6 mo of age. (A) Aβ40 and Aβ42 levels of APP23 and APP23/
TNFR1
−/− mice at 6 mo of age. (B) Western blots showed that BACE1 in 
APP23/TNFR1
−/− mice is much lower than that in PP23 mice at 6 mo of 
age. (C) RT-PCR showed that BACE1 mRNA in APP23/TNFR1
−/− mice is 
signiﬁ  cantly lower compared with APP23 mice at 6 mo of age. Error bars 
represent SD.
Figure 8.  Deletion of TNFR1 has no effect on IDE or NEP. (A) Western blots 
showing the density of IDE and NEP in brain lysates of wild-type, APP23/
TNFR1
−/−,and APP23 mice at 12 and 24 mo of age. (B) No signiﬁ  cant 
changes were observed in IDE activity between APP23 and APP23/
TNFR1
−/− mice. (C) No signiﬁ   cant differences in NEP activity between 
APP23 and APP23/TNFR1
−/− mice were found. Error bars represent SD. JCB • VOLUME 178 • NUMBER 5 • 2007  838
read at OD450 with a microplate reader (Sigma-Aldrich). BACE1 protein 
(Amgen) was used as a standard. Data are presented as means ± SD of 
four experiments.
Western blot
Aliquots of brain homogenates from APP23, APP23/TNFR1
−/−, and wild-
type mice were further lysed with 1× RIPA buffer, and 50–150 μg of total 
protein was subjected to SDS-PAGE (8–12% acrylamide). Separated pro-
teins were then transferred onto polyvinylidene ﬂ  uoride membranes. The 
blots were probed with the following antibodies: anti-BACE1 monoclonal 
antibody (R&D Systems), anti-Aβ (1–17) monoclonal antibody (clone 
6E10, 1:2,000; Chemicon), anti-IDE polyclonal antibody (Oncogene 
Research Products), anti-NEP polyclonal antibody (Chemicon), and anti–
β actin antibody (Sigma-Aldrich).
Western blotting for Aβ was performed as described previously 
(Wiltfang et al., 1997). To detect minute levels of Aβ, formic acid–
  dissolved brain tissue was immunoprecipitated with anti-Aβ polyclonal 
antibody (Zymed Laboratories) and subjected to SDS-PAGE using 10% 
acrylamide gels containing 8 M urea. Separated proteins were transferred 
onto polyvinylidene ﬂ  uoride membranes. Aβ40 and Aβ42 were detected 
with monoclonal anti-Aβ antibody 6E10. Synthetic Aβ40 and Aβ42 (Bio-
source International) were used as standards.
BACE1, IDE, and NEP activity
An aliquot of brain homogenates from APP23, APP23/TNFR1
−/−, and 
wild-type mice was further lysed with a lysis buffer (10 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 10% glyc-
erol, and 0.5% Triton X-100). BACE1 enzymatic activity assays were per-
formed by using synthetic peptide substrates containing BACE1 cleavage 
site (MCA-Glu-Val-Lys-Met-Asp-Ala-Glu-Phe-[Lys-DNP]-OH; Biosource Inter-
national). BACE substrate was dissolved in DMSO and mixed with a 
50-mM Hac and 100-mM NaCl, pH 4.1, reaction buffer. An equal amount 
of protein was mixed with 100 μl of substrate, and ﬂ  uorescence intensity 
was measured with a microplate reader (BioTek) at an excitation wave-
length of 320 nm and an emission wavelength of 390 nm.
IDE enzyme activity was measured as described previously (Song 
et al., 2003). In brief, brains were homogenized in 50 mM potassium phos-
phate buffer, pH 7.3, containing 200 μm PMSF and a proteinase inhibitor 
mix (Sigma-Aldrich). Samples were centrifuged and the supernatant fraction 
was used for IDE activity measurement. The hydrolysis of ﬂ  uorogenic 
substrate peptides (2 μm Abz-G  G  F  L  R  K  H  G  Q  E  D  -Dnp as substrate in 20 mM 
potassium phosphate buffer, pH 7.3) was measured by following an 
  increase in ﬂ  uorescence (excitation at 318 nm and emission at 419 nm) 
that occurred upon peptide bond cleavage. The max velocity of IDE activity 
was calculated by the ﬁ  rst 20 min and indicated as ﬂ  uorescence unit/min 
microgram protein.
For the in vitro NEP activity assay, mouse brains were homogenized 
in 100 mM MES buffer (pH 6.5) with proteinase inhibitors (Sigma-Aldrich). 
Homogenate was centrifuged at 20,000 g for 45 min to separate the 
membrane fraction and the supernatant was removed. The membrane pel-
let was resuspended in MES buffer and directly used in NEP activity assay 
as previously described (Li and Hersh, 1995).
RT-PCR
To compare BACE1 expression levels, we used the following primers for 
RT-PCR: mouse BACE1 forward primer, 5′-A  G  A  C  G  C  T  A  C  A  C  A  T  C  C  T  G  G  T  G  -3′, 
and backward primer, 5′-C  C  T  G  G  G  T  G  T  A  G  G  G  C  A  C  A  T  A  C  -3′. The ampliﬁ  ed 
BACE1 fragment was 146 bp. Mouse s18 was used as a loading control: 
forward primer, 5′-C  A  G  A  A  G  G  A  C  G  T  G  A  A  G  G  A T  G  G  -3′, and backward primer, 
5′-C  A  G  T  G  G  T  C  T  T  G  G  T  G  T  G  C  T  G  A  -3′. The ampliﬁ  ed mouse s18 fragment 
was 159 bp. Total RNA was extracted from the brains of 12-mo-old APP23 
and APP23/TNFR1
−/− mice (n = 5) using an RNA mini column kit (Invitrogen). 
RT-PCR was performed using a One- Step RT-PCR kit (Invitrogen) and the 
following PCR cycles: 50°C for 30 min, 94°C for 2 min, followed by 25 
cycles at 94°C for 15 s, 49°C for 30 s, and 68°C for 1 min.
Cell transfection and luciferase assay
We transfected 293 cells with pB1P-A vector containing a BACE1 promoter 
(−1941 to +292) upstream from a luciferase reporter gene (Christensen 
et al., 2004) using lipofectamine (Invitrogen). After transfection, cells were 
treated with different concentrations of TNFα (R&D Systems), extracellular 
domain of TNFR1 (R&D Systems), or NF-κB inhibitor 6-amino-4(4-phenoxy-
phenylethylamino) quinazoline (Calbiochem; Tobe et al., 2003). Cells 
were collected 12 h after treatment, and a luciferase assay (Promega) 
was performed, according to the manufacturer’s instructions. Lumines-
cence intensity was measured with a microplate reader, normalized ac-
cording to protein amount, and plotted as relative luminescence units per 
milligram of protein.
Immunohistochemistry and immunoﬂ  uorescence
Immunohistochemistry was performed as previously described (Matsuoka 
et al., 2001). In brief, paraformaldehyde-ﬁ  xed brains were quickly frozen, 
and then sectioned at 30 μm. Sections were incubated with either anti-Aβ 
(6E10 clone or 4G8 clone, 1:1,000; Chemicon), anti-NeuN (MAB377, 
Figure 9.  Deletion of TNFR1 in APP23 mice reduces 
neuron loss. (A) Fewer NeuN-positive neurons were 
present in the entorhinal cortex of APP23 mice at the 
age of 24 mo. (B) NeuN immunostaining demonstrated 
little neuronal loss in the CA1 ﬁ  eld in APP23/TNFR1
−/− 
mice. (C) Statistical analyses show that APP23 mice 
had signiﬁ  cantly fewer neurons in the entorhinal cortex 
at 24 mo of age (*, P < 0.01). (D) Statistical analyses 
show APP23 mice had signiﬁ  cantly fewer neurons in the 
CA1 of the hippocampus at 24 mo of age (*, P < 0.01). 
Error bars represent SD. Bars, 10 μm. TNFR1 AFFECTS APP PROCESSING AND MEMORY • HE ET AL. 839
1:400; Chemicon), anti-CD11b (MCA711, 1:500; AbD Serotec) and 
CD45 (MCA1388, 1:500; AbD Serotec), anti-α-smooth muscle actin (α-SM 
actin, A2547, 1:400; Sigma-Aldrich), or anti-vWF (AB7536, 1:200; 
Chemicon). Secondary antibodies were applied with horse anti–mouse (for 
6E10, NeuN detection, 1:1,000) and goat anti–rat (for CD45 or CD11b, 
1:1,000) followed by a DAB substrate (Vector Laboratories). For immuno-
ﬂ  uorescence, ﬂ  uorescent-labeling 488 (green) or 594 (red) secondary anti-
bodies against rabbit IgG or mouse IgG were used (1:1,000; Invitrogen). 
A microscope (DMLS; Leica) with a 10× N PLAN and 20× and 40× PL 
FLUOTAR was used. Digital images were captured and processed by digital 
camera (Optronics) and MagnaFire software (version 2.1C; Optronics).
Quantitation of immunoreactive structures
30-μm serial sagittal sections through the entire rostrocaudal extent of the 
hippocampus were cut on a cryostat. Every 10th section was immuno-
stained with anti-NeuN antibody. On all sections containing the hippo-
campus, we delineated the pyramidal cell layer CA1. The total number of 
neurons were obtained using unbiased stereology (Casas et al., 2004; 
Schmitz et al., 2004) and a microscope equipped with a digital camera 
(DEI-470; Optronics). For each section, we delineated a 400-μm
2 area in 
CA1 and in the entorhinal cortex and counted all NeuN-immunoreactive 
cells within that 400-μm
2 box. The mean sum of neurons was counted per 
animal (n = 10). We used the same method to count Aβ-immunoreactive 
plaques (stained with 6E10) in the hippocampus and entorhinal cortex in 
a double blind test. We also measured the diameter of each counted 
plaque. Differences between groups were tested with Image-pro Plus Analysis 
(Media Cybernetics).
Hole-board memory task
As previously reported (Dodart et al., 2002), this task measured a mouse’s 
ability to remember which one out of four equidistant holes was baited with 
food. Two photobeam apparatuses were used with a hole board for assessing 
directed exploration in mice for behavioral tests. A tested mouse (n = 10 
for each group) was placed in the center of the hole-board and the number 
of nose pokes was automatically registered for 5 min. After 20 min, each 
animal was placed in a corner of the hole board and allowed to freely 
explore the apparatus for 5 min. The number of head dips, time spent 
head-dipping, and the number of rearings were recorded. A comprehensive 
cognitive performance was determined by calculating the mean number of 
correct pokes per trial that mouse made each day. Cognition was expressed 
as the percentage of correct pokes. The measurements in the hole-board 
test were analyzed by unpaired t test. In all cases the signiﬁ  cance level was 
considered to be P < 0.05, and the very signiﬁ  cant level was considered 
to be P < 0.01.
Object recognition task
The day before training, an individual mouse (n = 10 for each group) was 
placed into a training apparatus (a box the same size as described for the 
hole-board test) and allowed to habituate to the environment for 15 min. 
Training was initiated 24 h after habituation. A mouse was placed back 
into the training box containing two identical objects A and B (die or marble) 
and allowed to explore these objects. Among experiments, training times 
varied from 3.5 to 20 min. For each experiment, the same set of animals 
was used repeatedly with different sets of objects for each repetition. Five 
repetitions were performed on each set of mice. Each mouse was 
trained and tested no more than once per week, with a 1-wk interval be-
tween testing. Moreover, each experimental condition was replicated inde-
pendently four times. In each experiment, the experimenter was blinded to 
the subjects during training and testing. To test memory retention, mice 
were observed for 10 min, 6 h, and 24 h after training. Mice were pre-
sented with two objects, one that was used during training, and thus was 
‘‘familiar,’’ and one that was novel. The test objects were divided into 10 
sets of ‘‘training’’ plus ‘‘testing’’ objects, and a new set of objects was used for 
each training session. A recognition index was calculated for each mouse, 
expressed as the ratio (100TB)×(TA + TB), where TA and TB are the time 
spent during the second trial on subject A and subject B, respectively. 
To ensure that the discrimination targets did not differ in odor, the appara-
tus and the objects were thoroughly cleaned with 90% ethanol, dried, and 
ventilated for a few minutes after each experiment.
Statistical analyses
In general, analysis of variance models (ANOVA) were used to analyze 
behavioral data. Typically, the statistical models included two between-
subjects variables, the genotype of mice (APP23 vs. APP23/TNFR1
−/−) 
and age, and one within-subjects variable, such as blocks of trials. When 
ANOVAs with repeated measures were conducted, the Huynh-Feldt adjust-
ment of α levels was used for all within-subjects effects containing more 
than two levels to protect against violations of the sphericity/compound 
symmetry assumptions underlying this ANOVA model.
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